{"nctId":"NCT05299242","briefTitle":"The Anti-Freaze-F Study- \"Anti-TNF for Treatment of Frozen Shoulder - a Feasibility Study\"","startDateStruct":{"date":"2022-07-21","type":"ACTUAL"},"conditions":["Frozen Shoulder"],"count":9,"armGroups":[{"label":"Arm A","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Adalimumab Injection"]},{"label":"Arm B","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Adalimumab Injection","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Men and women aged 18 years and above.\n2. With a new episode of shoulder pain attributable to pain-predominant stage of frozen shoulder (i.e. within approximately 3 months of onset of symptoms) diagnosed using criteria set out in the BESS guidelines (33) (Appendix 1);\n3. Who are not being considered for surgery;\n4. Able to understand spoken and written English;\n5. Willing and able to give informed consent for trial participation and comply with all study requirements and time line;\n6. Willing to allow his or her General Practitioner be notified of participation in the trial.\n7. If female and of child-bearing potential OR if male and their partner is of child-bearing potential - willing to use effective contraception throughout the treatment period and for 5 months after the last injection.-\n\nExclusion Criteria:\n\n1. Those with frozen shoulder secondary to significant shoulder trauma (e.g., dislocation, fracture or full thickness tear requiring surgery) or other causes (e.g. recent breast cancer surgery or radiotherapy);\n2. Those with a neurological disease affecting the shoulder;\n3. Those with bilateral concurrent frozen shoulder;\n4. Those with other shoulder disorders (e.g., inflammatory arthritis, rotator cuff disorders, glenohumeral joint instability) or with red flags consistent with the criteria set out in the BESS guidelines (33);\n5. Those who have received corticosteroid injection for shoulder pain in the last 12 weeks to either shoulder;\n6. Those currently taking any anti-TNF drug;\n7. Those being treated with coumarin anticoagulants, such as warfarin;\n8. Those who have participated in another research study involving an investigational medicinal product in the past 12 weeks;\n9. Those with significant renal or hepatic impairment;\n10. Those with contra-indications to anti-TNF injection:\n\n10.1 Known allergy to any anti-TNF agent or any of the excipients; 10.2 Known Active tuberculosis (TB) or history of TB. 10.3 Known Active infection (chronic or localised) or known history of recurring infections or condition which may predispose patients to infection, including the use of concomitant immunosuppressive medications; 10.4 Known Moderate to severe heart failure (NYHA class III/IV); 10.5 Those known to have HIV, Hepatitis B or C; 10.6 Those at risk of Hepatitis B infection; 10.7 Those diagnosed with Multiple Sclerosis (MS) or other central or peripheral nervous system demyelinating disorders; 10.8 Those who have ever been diagnosed with cancer, except basal cell carcinoma (BCC); 10.9 Those requiring live vaccination prior to within 12 weeks after of the last trial injection or within the 4 weeks prior to randomisation; 10.10 Those taking biologic DMARDS; 10.11 Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Eligible With Pain Predominant Frozen Shoulder","description":"Ability to screen and identify potential participants with pain-predominant early stage frozen shoulder (i.e. within approximately 3 months of onset of symptoms).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Consenting to be Included in the Trial","description":"Willingness of eligible participants to consent and be randomised to intervention.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]}]},{"type":"PRIMARY","title":"Time From Randomisation to First Injection","description":"Practicalities of delivering the intervention, including time to first injection (within 2 weeks of randomisation).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.3","spread":"4.8"},{"groupId":"OG001","value":"7.2","spread":"4.1"}]}]}]},{"type":"PRIMARY","title":"Time From First Injection to Second Injection","description":"Practicalities of delivering the intervention, including time between first injection and second injection (within 4-6 weeks of randomisation).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.5","spread":"3.3"},{"groupId":"OG001","value":"20.8","spread":"5.9"}]}]}]},{"type":"PRIMARY","title":"Shoulder Pain and Disability Index (SPADI) Score","description":"Score ranges from 0 to 100, lower scores indicate better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.8","spread":"16.6"},{"groupId":"OG001","value":"55.4","spread":"21.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.1","spread":"30.0"},{"groupId":"OG001","value":"45.8","spread":"25.3"}]}]}]},{"type":"SECONDARY","title":"Pain (Shoulder Pain And Disability Index, 5-item Subscale)","description":"Score ranges from 0 to 100, lower scores indicate better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.5","spread":"18.4"},{"groupId":"OG001","value":"63.2","spread":"19.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.5","spread":"32.7"},{"groupId":"OG001","value":"49.6","spread":"27.3"}]}]}]},{"type":"SECONDARY","title":"Function (Shoulder Pain And Disability Index, 8-item Subscale)","description":"Score ranges from 0 to 100, lower scores indicate better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.1","spread":"15.6"},{"groupId":"OG001","value":"47.5","spread":"25.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.8","spread":"30.3"},{"groupId":"OG001","value":"42.0","spread":"24.7"}]}]}]},{"type":"SECONDARY","title":"Fear Avoidance Belief Questionnaire","description":"Score ranges from 0 to 24, higher scores indicate better outcomes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.3","spread":"3.3"},{"groupId":"OG001","value":"17.4","spread":"3.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.3","spread":"6.2"},{"groupId":"OG001","value":"12.8","spread":"5.9"}]}]}]},{"type":"SECONDARY","title":"Pain Self Efficacy Questionnaire","description":"Score ranges from 0 to 12, higher scores indicate better outcomes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":"3.6"},{"groupId":"OG001","value":"9.2","spread":"1.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":"1.3"},{"groupId":"OG001","value":"8.2","spread":"2.8"}]}]}]},{"type":"SECONDARY","title":"Insomnia Severity Index","description":"Sleep disturbance measured using the Insomnia Severity Index, score ranges from 0 to 28, higher scores indicate worse outcomes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.8","spread":"5.0"},{"groupId":"OG001","value":"17.6","spread":"4.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":"6.7"},{"groupId":"OG001","value":"13.2","spread":"7.6"}]}]}]},{"type":"SECONDARY","title":"Return to Desired Activities (RDA)","description":"Return to desired activities measured using an adapted version of the Disabilities of the Arm, Shoulder and Hand (QUICKDASH) questionnaire. Score ranges from 3 to 15, lower scores indicate better outcomes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":"4.5"},{"groupId":"OG001","value":"9.4","spread":"2.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"3.8"},{"groupId":"OG001","value":"8.4","spread":"3.6"}]}]}]},{"type":"SECONDARY","title":"Global Impression of Change","description":"This was measured using the Likert scale. Score ranges from -5 (very much worse) to +5 (completely recovered) with a value of 0 suggesting no change. Higher scores indicate better outcomes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"2.2"},{"groupId":"OG001","value":"0.0","spread":"3.0"}]}]}]},{"type":"SECONDARY","title":"Health Resource Use","description":"Consultation with primary and secondary care, additional physiotherapy, injection use, or alternative therapies for index shoulder","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Adverse Events Graded 3 or Above","description":"Any adverse event (graded 3 or above) that has resulted from the trial.\n\nThe Common Terminology Criteria for Adverse Events (CTCAE) v5.0 was used to guide recording adverse events including grading of the event. Grade 3: Severe symptoms or medically significant but not life-threatening but may be disabling or limit self care in Activities of Daily Living. Grade 4: Life threatening consequences; urgent or emergent intervention needed. Grade 5: Death related to or due to adverse event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Shoulder Range of Movement","description":"Clinician assessed (goniometry measured) active shoulder flexion, extension, abduction, internal and external rotation. Range of flexion and abduction: 0-180 degrees. Range of extension, internal rotation and external rotation: 0-90 degrees.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.3","spread":"26.3"},{"groupId":"OG001","value":"101.6","spread":"24.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"112.5","spread":"54.8"},{"groupId":"OG001","value":"140.0","spread":"25.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.3","spread":"18.0"},{"groupId":"OG001","value":"27.6","spread":"9.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.0","spread":"8.2"},{"groupId":"OG001","value":"40.6","spread":"9.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":"30.3"},{"groupId":"OG001","value":"69.0","spread":"26.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"105.0","spread":"56.1"},{"groupId":"OG001","value":"115.0","spread":"42.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.8","spread":"18.9"},{"groupId":"OG001","value":"40.2","spread":"40.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.3","spread":"17.0"},{"groupId":"OG001","value":"41.0","spread":"37.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.5","spread":"8.7"},{"groupId":"OG001","value":"15.0","spread":"16.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.8","spread":"6.3"},{"groupId":"OG001","value":"55.0","spread":"16.2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":4},"commonTop":[]}}}